Lee Financial Co initiated a position in UnitedHealth Group in the third quarter, acquiring 3,390 shares valued at approximately 1.17 million dollars, according to its latest SEC Form 13F. Brighton Jones LLC followed suit in the fourth quarter, boosting its holdings by 176.2% to 44,249 shares, now carrying a market value of 22.38 million dollars. Revolve Wealth Partners LLC more than doubled its exposure, adding 2,324 shares in the same period for a total of 4,019 shares valued at 2.03 million dollars. European investor CMT Capital Markets Trading GmbH entered the stock in the second quarter with a new stake worth around 340,000 dollars, while Patriot Financial Group Insurance Agency LLC expanded by 42.5%, bringing its total to 5,312 shares valued at 1.66 million dollars. Montz Harcus Wealth Management LLC modestly increased its stake by 12.2% to 679 shares, worth 212,000 dollars. Collectively, hedge funds and institutional players now own nearly 88% of the company’s shares, underscoring strong professional interest in the healthcare conglomerate.

Equity research firms have issued a flurry of updates on UnitedHealth Group. Jefferies Financial Group retained its buy rating but trimmed its target from 418 to 340 dollars, citing valuation concerns. Oppenheimer lowered its objective from 415 to 385 dollars while maintaining an outperform stance. TD Cowen bucked the trimming trend by raising its target slightly to 338 dollars but assigned a hold rating. KeyCorp reaffirmed an overweight recommendation without changing its forecast, and Zacks Research upgraded the stock from strong sell to hold. Across 29 analysts tracked by MarketBeat, one recommends strong buy, 17 advise buy, nine suggest hold and two issue sell opinions, yielding an average Moderate Buy consensus and a target price of 376.75 dollars.

In its latest quarter, UnitedHealth reported adjusted earnings per share of 2.11 dollars, narrowly surpassing the consensus estimate by 0.02 dollars, on revenue of 113.22 billion dollars, slightly below forecasts. Net margin stood at 2.69% and return on equity at 14.79%, while quarterly revenue growth of 12.3% year-over-year fell short of the anticipated 113.38 billion dollars. Management set full-year EPS guidance at approximately 17.75 dollars, against a current consensus of 29.54 dollars, reflecting a cautious outlook. The firm’s balance sheet shows a debt-to-equity ratio of 0.72, a quick ratio of 0.82 and a current ratio of 0.79. Market capitalization remains near 260 billion dollars, with a price-to-earnings ratio of 21.76 and a PEG of 1.35, emphasizing a premium valuation relative to projected growth.

UnitedHealth declared a quarterly dividend of 2.21 dollars per share, paid December 16 to record holders as of December 8, translating to an annualized payout of 8.84 dollars and a yield of roughly 3.1%. The company’s dividend payout ratio stands at 67.02%, indicating that two-thirds of net earnings return to shareholders. With a one-year share price range from 234.60 to 606.36 dollars, the dividend policy underscores the board’s commitment to consistent income distribution even as market volatility and guidance revisions shape the stock’s trajectory.